Free Trial

Oncolytics Biotech (ONC) Insider Trading & Ownership

Oncolytics Biotech logo
C$1.38 -0.02 (-1.43%)
(As of 01:31 PM ET)

Oncolytics Biotech (TSE:ONC) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
3.82%
Number Of
Insiders Buying
(Last 3 Years)
3
Amount Of
Insider Buying
(Last 3 Years)
C$17,726.86
Number Of
Insiders Selling
(Last 3 Years)
0
Get ONC Insider Trade Alerts

Want to know when executives and insiders are buying or selling Oncolytics Biotech stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

ONC Insider Buying and Selling by Quarter

Oncolytics Biotech Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/16/2022Allison HagermanSenior OfficerBuy4,200C$1.16C$4,851.00
6/14/2022Kirk LookSenior OfficerBuy6,000C$1.11C$6,656.40
6/14/2022Matthew CoffeyDirectorBuy5,774C$1.08C$6,219.46
(Data available from 1/1/2013 forward)

ONC Insider Trading Activity - Frequently Asked Questions

The list of insiders at Oncolytics Biotech includes Allison Hagerman, Kirk Look, and Matthew Coffey. Learn more on insiders at ONC.

3.82% of Oncolytics Biotech stock is owned by insiders. Learn more on ONC's insider holdings.

Oncolytics Biotech Key Executives

  • Dr. Matthew C. Coffey M.B.A.
    Ph.D., President, CEO & Director
  • Mr. Kirk J. Look C.A.
    CA, Chief Financial Officer
  • Dr. Thomas C. Heineman M.D.
    Ph.D., Chief Medical Officer
  • Ms. Allison Hagerman P.Eng.
    P.M.P., Vice President of Product Development
  • Ms. Amy Goodowitz Levin B.S.N.
    R.N., Vice President of Clinical Operations
  • Jon Patton
    Director of Investor Relations & Communication
  • Mr. John Mark Lievonen BBA
    C.M., FCA, LLD, MBA, Consultant


This page (TSE:ONC) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners